• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Raltitrexed plus radiotherapy for the treatment of unresectable/recurrent rectal cancer: a phase I study.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    James, Roger D
    Botwood, Nicholas
    Vernon, C
    Price, Patricia M
    Affiliation
    The Kent Oncology Centre, Maidstone Hospital, UK. rjames@koc.mtw-tr.nhs.uk
    Issue Date
    2003-04
    
    Metadata
    Show full item record
    Abstract
    BACKGROUND: Current consensus is that a combination of radiotherapy and chemotherapy may provide the optimal treatment for patients with unresectable rectal cancer. Raltitrexed has proven efficacy in the treatment of advanced colorectal cancer and has an acceptable toxicity profile. The aim of this phase I study was to determine the recommended dose of raltitrexed in combination with radiotherapy in patients with unresectable/recurrent rectal cancer. PATIENTS AND METHODS: Patients were treated with radiotherapy (25 fractions at 2.0 Gy per fraction) five times per week for 5 weeks. Raltitrexed was administered on days 1 and 22 at 2.0, 2.6 and 3.0 mg/m(2). RESULTS: A total of 20 patients were entered into the study. Dose-limiting toxicities were recorded in three of 20 patients following the first dose of raltitrexed; one patient at 2.6 mg/m(2) (grade 3 diarrhoea, grade 3 neutropenia and grade 2 pyrexia) and two patients at 3.0 mg/m(2) (one grade 3 neutropenia and one grade 4 diarrhoea). The most common non-haematological and haematological treatment-related adverse events were diarrhoea (11 of 20, two grade 3, one grade 4) and leukopenia (eight of 20, one grade 3, one grade 4), respectively. CONCLUSIONS: The recommended dose of raltitrexed in combination with radiotherapy for future studies is 2.6 mg/m(2).
    Citation
    Raltitrexed plus radiotherapy for the treatment of unresectable/recurrent rectal cancer: a phase I study. 2003, 14 (4):570-3 Ann. Oncol.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/79074
    DOI
    10.1093/annoc/mdg165
    PubMed ID
    12649103
    Type
    Article
    Language
    en
    ISSN
    0923-7534
    ae974a485f413a2113503eed53cd6c53
    10.1093/annoc/mdg165
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Raltitrexed ('Tomudex') and radiotherapy can be combined as postoperative treatment for rectal cancer.
    • Authors: Botwood N, James R, Vernon C, Price P
    • Issue date: 2000 Aug
    • Raltitrexed and radiotherapy as adjuvant treatment for stage II-III rectal cancer: a feasibility study.
    • Authors: Lupattelli M, Maranzano E, Bellavita R, Natalini G, Corgna E, Rossetti R, Trippa F, Mascioni F, Sidoni A, Anselmo P, Buzzi F, Brugia M, Latini P
    • Issue date: 2005 Nov-Dec
    • Oxaliplatin with raltitrexed and preoperative radiotherapy in T3-T4 extraperitoneal rectal cancer. A dose finding study.
    • Authors: Lupattelli M, Bellavita R, Natalini G, Giovenali P, Sidoni A, Castagnoli P, Corgna E, Draghini L, Trippolini R, Aristei C
    • Issue date: 2006 Nov-Dec
    • Preoperative chemoradiation with raltitrexed ('Tomudex') for T2/N+ and T3/N+ rectal cancers: a phase I study.
    • Authors: Valentini V, Doglietto GB, Morganti AG, Turriziani A, Smaniotto D, De Santis M, Ratto C, Sofo L, Cellini N
    • Issue date: 2001 Nov
    • Neoadjuvant accelerated concomitant boost radiotherapy and multidrug chemotherapy in locally advanced rectal cancer: a dose-escalation study.
    • Authors: Caravatta L, Picardi V, Tambaro R, Padula GD, Macchia G, Deodato F, Massaccesi M, Pacelli F, Berardi S, Ridolfini MP, Di Filippo L, Fabrizio G, Ingrosso M, Cellini N, Valentini V, Morganti AG
    • Issue date: 2012 Oct
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.